nach oben

Erschienen in:

01.02.2012 | PRECLINICAL STUDIES

K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV)—associated nasopharyngeal carcinoma cells

verfasst von: Yuen-Keng Ng, Elaine Yue Ling Wong, Cecilia Pik Yuk Lau, Jessica Pui Lan Chan, Sze Chuen Cesar Wong, Andrew Sai-Kit Chan, Maggie Pui Chun Kwan, Sai-Wah Tsao, Chi-Man Tsang, Paul Bo San Lai, Anthony Tak Cheung Chan, Vivian Wai Yan Lui

Erschienen in: Investigational New Drugs | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Summary

Recent studies revealed an unexpected role of the neurotrophin receptor pathway, BDNF/TrkB signaling, in cancer metastasis and anoikis (i.e. detachment-induced cell death). Survival of cancer cells in detached state (known as anoikis-resistance) is known to be pre-requisite for metastasis. Nasopharyngeal carcinoma (NPC), an endemic head and neck cancer in Southeast Asia, is highly invasive, metastatic, and etiologically associated with Epstein-Barr virus (EBV, an oncovirus) infection. Mechanistic studies on the invasive/metastatic nature of NPC can facilitate the development of anti-metastatic therapy in NPC. Thus far, the role of BDNF/TrkB signaling in virus-associated human cancer is unclear. Here, using multiple cell line models of NPC with EBV-association (HONE-1-EBV, HK1-LMP1 and C666-1), we investigated the potential involvement of BDNF/TrkB signaling in cellular migration and anoikis-resistant characteristics of NPC. We found that all three EBV-associated NPC cell lines tested were intrinsically anoikis-resistant (i.e. survived in detached state) and expressed both BDNF and TrkB. BDNF stimulation induced cellular migration, but not proliferation of these cells. Further, we examined if pharmacologic targeting of anoikis-resistance of NPC cells can be achievable by a proof-of-concept Trk inhibitor, K252a, in these EBV-associated NPC models. Our results demonstrated that K252a, was able to attenuate BDNF-induced migration and proliferation of NPC cells. More importantly, we demonstrated for the first time that K252a harbored potent anoikis-sensitization activity (i.e. sensitizing cancer cells to detachment-induced cell death) against EBV-associated human cancer cells, namely NPC cells. This proof-of-concept study demonstrated that K252a, a Trk inhibitor, can potentially be used as an anoikis-sensitizing agent in NPC.

Nur mit Berechtigung zugänglich

Raab-Traub N (2002) Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12(6):431–441PubMedCrossRef

Niedobitek G (1999) The Epstein-Barr virus: a group 1 carcinogen? Virchows Arch 435(2):79–86PubMedCrossRef

Chan AT, Teo PM, Johnson PJ (2002) Nasopharyngeal carcinoma. Ann Oncol 13(7):1007–1015PubMedCrossRef

Anderson KE, Mack TM, Silverman DT (2006) Cancer of the pancreas. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York, NY, pp 721–762

Fandi A, Altun M, Azli N et al (1994) Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 21(3):382–397PubMed

Burt RD, Vaughan TL, McKnight B (1992) Descriptive epidemiology and survival analysis of nasopharyngeal carcinoma in the United States. Int J Cancer 52(4):549–556PubMedCrossRef

Yeung WM, Zong YS, Chiu CT et al (1993) Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int J Cancer 53(5):746–750PubMedCrossRef

Dickens P, Srivastava G, Loke SL et al (1992) Epstein-Barr virus DNA in nasopharyngeal carcinomas from Chinese patients in Hong Kong. J Clin Pathol 45(5):396–397PubMedCrossRef

Klein G, Giovanella BC, Lindahl T et al (1974) Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A 71(12):4737–4741PubMedCrossRef

10.

Lui VW, Wong EY, Ho Y et al (2009) STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer 125(8):1884–1893PubMedCrossRef

11.

Chang SH, Chang HC, Hung WC (2008) Transcriptional repression of tissue inhibitor of metalloproteinase-3 by Epstein-Barr virus latent membrane protein 1 enhances invasiveness of nasopharyngeal carcinoma cells. Oral Oncol 44(9):891–897PubMedCrossRef

12.

Tsuji A, Wakisaka N, Kondo S et al (2008) Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma. Clin Cancer Res 14(17):5368–5375PubMedCrossRef

13.

Ho CH, Chen CL, Li WY et al (2009) Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis 30(8):1443–1451PubMedCrossRef

14.

Agulnik M, Epstein JB (2008) Nasopharyngeal carcinoma: current management, future directions and dental implications. Oral Oncol 44(7):617–627PubMedCrossRef

15.

Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124(4):619–626PubMedCrossRef

16.

Wang X-C, Wu Y-P, Ye B et al (2009) Suppression of anoikis by SKP2 amplification and overexpression promotes metastasis of esophageal squamous cell carcinoma. Mol Canc Res 7(1):12–22CrossRef

17.

Zhang X, Su L, Pirani A et al (2006) Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. Clin Exp Metastasis 23(3):209PubMedCrossRef

18.

Duxbury MS, Ito H, Zinner MJ et al (2004) Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery 135(5):555PubMedCrossRef

19.

Duxbury MS, Ito H, Zinner MJ, et al. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 23(2):465

20.

Swan EA, Jasser SA, Holsinger FC et al (2003) Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol 39(7):648PubMedCrossRef

21.

Zhu Z, Sanchez-Sweatman O, Huang X et al (2001) Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 61(4):1707–1716PubMed

22.

Geiger TR, Peeper DS (2007) Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res 67(13):6221–6229PubMedCrossRef

23.

Geiger TR, Peeper DS (2005) The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res 65(16):7033–7036PubMedCrossRef

24.

Douma S, Van Laar T, Zevenhoven J et al (2004) Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430(7003):1034–1039PubMedCrossRef

25.

Zhang Z, Han L, Liu Y et al. (2008) Up-regulation of tropomyosin related kinase B contributes to resistance to detachment-induced apoptosis in hepatoma multicellular aggregations. Mol Biol Rep

26.

Zhang Z, Cao L, Li J et al (2008) Acquisition of anoikis resistance reveals a synoikis-like survival style in BEL7402 hepatoma cells. Cancer Lett 267(1):106–115PubMedCrossRef

27.

Yu X, Liu L, Cai B et al (2008) Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Science 99(3):543–552PubMedCrossRef

28.

Sclabas GM, Fujioka S, Schmidt C et al (2005) Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 11(2):440–449PubMed

29.

Martin-Zanca D, Hughes SH, Barbacid M (1986) A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 319(6056):743–748PubMedCrossRef

30.

Katzav S, Martin-Zanca D, Barbacid M et al (1989) The trk oncogene abrogates growth factor requirements and transforms hematopoietic cells. Oncogene 4(9):1129–1135PubMed

31.

Mawji IA, Simpson CD, Gronda M et al (2007) A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Res 67(17):8307–8315PubMedCrossRef

32.

Evans AE, Kisselbach KD, Yamashiro DJ et al (1999) Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 5(11):3594–3602PubMed

33.

Wang Y, Hagel C, Hamel W et al (1998) Trk A, B, and C are commonly expressed in human astrocytes and astrocytic gliomas but not by human oligodendrocytes and oligodendroglioma. Acta Neuropathol 96(4):357–364PubMedCrossRef

34.

Wadhwa S, Nag TC, Jindal A et al (2003) Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma. J Biosci 28(2):181–188PubMedCrossRef

35.

Yang ZF, Ho DW, Lam CT et al (2005) Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. Cancer Res 65(1):219–225PubMed

36.

Kupferman ME, Jiffar T, El-Naggar A et al (2010) TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 29(14):2047–2059PubMedCrossRef

37.

Zhao W, Wen W, Zhang Z et al (2007) Expression and significance of tyrosine kinase receptors B in nasopharyngeal carcinoma patients. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 21(11):497–500PubMed

38.

Anderson RA, Robinson LL, Brooks J et al (2002) Neurotropins and their receptors are expressed in the human fetal ovary. J Clin Endocrinol Metab 87(2):890–897PubMedCrossRef

39.

Hong B, Lui VW, Hui EP et al. (2009) Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. Invest New Drugs

40.

Lui VW, Boehm AL, Koppikar P et al (2007) Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol 71(5):1435–1443PubMedCrossRef

41.

Lui VW, Thomas SM, Zhang Q et al (2003) Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 22(40):6183–6193PubMedCrossRef

42.

Lui VW, Yau DM, Wong EY et al (2009) Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 30(12):2085–2094PubMedCrossRef

43.

Diaz-Montero CM, Wygant JN, McIntyre BW (2006) PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur J Cancer 42(10):1491–1500PubMedCrossRef

44.

Akinaga S, Ashizawa T, Gomi K et al (1992) Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action. Cancer Chemother Pharmacol 29(4):266–272PubMedCrossRef

45.

Festuccia C, Gravina GL, Muzi P et al (2007) In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. Prostate 67(12):1255–1264PubMedCrossRef

46.

Perez-Pinera P, Hernandez T, Garcia-Suarez O et al (2007) The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas. Mol Cell Biochem 295(1–2):19–26PubMedCrossRef

47.

Miknyoczki SJ, Chang H, Klein-Szanto A et al (1999) The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin Cancer Res 5(8):2205–2212PubMed

48.

Miknyoczki SJ, Dionne CA, Klein-Szanto AJ et al (1999) The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann N Y Acad Sci 880:252–262PubMedCrossRef

49.

Morotti A, Mila S, Accornero P et al (2002) K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21(32):4885–4893PubMedCrossRef

50.

Takai N, Ueda T, Nishida M et al (2005) K252a inhibits proliferation of ovarian cancer cells by upregulating p21WAF1. Oncol Rep 14(1):141–143PubMed

51.

Takai N, Ueda T, Nishida M et al (2008) K252a is highly effective in suppressing the growth of human endometrial cancer cells, but has little effect on normal human endometrial epithelial cells. Oncol Rep 19(3):749–753PubMed

52.

Marshall JL, Kindler H, Deeken J et al (2005) Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 23(1):31–37PubMedCrossRef

53.

Undevia SD, Vogelzang NJ, Mauer AM et al (2004) Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs 22(4):449–458PubMedCrossRef

54.

Strock CJ, Park JI, Rosen M et al (2003) CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 63(17):5559–5563PubMed

55.

Smith BD, Levis M, Beran M et al (2004) Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103(10):3669–3676PubMedCrossRef

56.

Thress K, Macintyre T, Wang H et al (2009) Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther 8(7):1818–1827PubMedCrossRef

57.

Cazorla M, Jouvenceau A, Rose C et al (2010) Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS One 5(3):e9777PubMedCrossRef

Titel: K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV)—associated nasopharyngeal carcinoma cells
verfasst von: Yuen-Keng Ng
Elaine Yue Ling Wong
Cecilia Pik Yuk Lau
Jessica Pui Lan Chan
Sze Chuen Cesar Wong
Andrew Sai-Kit Chan
Maggie Pui Chun Kwan
Sai-Wah Tsao
Chi-Man Tsang
Paul Bo San Lai
Anthony Tak Cheung Chan
Vivian Wai Yan Lui
Publikationsdatum: 01.02.2012
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 1/2012
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9513-4

Springer Medizin

K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV)—associated nasopharyngeal carcinoma cells

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy

A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis

3β-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression

A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma

A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie